MIRA Pharmaceuticals (NASDAQ:MIRA) Issues Earnings Results, Beats Expectations By $0.06 EPS

MIRA Pharmaceuticals (NASDAQ:MIRA) posted its earnings results on Tuesday. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.06, FiscalAI reports.

MIRA Pharmaceuticals Trading Up 11.1%

NASDAQ:MIRA opened at $1.07 on Wednesday. The stock has a market capitalization of $44.81 million, a P/E ratio of -0.70 and a beta of 1.78. MIRA Pharmaceuticals has a 1 year low of $0.73 and a 1 year high of $2.45. The firm has a 50 day moving average of $1.20 and a 200-day moving average of $1.36.

Institutional Investors Weigh In On MIRA Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. XTX Topco Ltd bought a new position in MIRA Pharmaceuticals in the 2nd quarter valued at $26,000. Creative Planning acquired a new stake in shares of MIRA Pharmaceuticals in the second quarter valued at $27,000. Two Sigma Investments LP increased its stake in shares of MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after buying an additional 25,816 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of MIRA Pharmaceuticals by 100.0% in the fourth quarter. Geode Capital Management LLC now owns 272,878 shares of the company’s stock valued at $412,000 after buying an additional 136,438 shares during the last quarter. 35.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MIRA shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MIRA Pharmaceuticals in a report on Friday. Rodman & Renshaw assumed coverage on MIRA Pharmaceuticals in a research report on Tuesday, January 13th. They set a “buy” rating for the company. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, MIRA Pharmaceuticals has a consensus rating of “Hold”.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.